Abstract The MLH1 c.2252_2253delAA mutation was found in 11 unrelated families from a restricted area southwest of Turin among 140 families with mutations in the mismatch repair genes. The mutation is located in the highly conserved C-terminal region, responsible for dimerization with the PMS2 protein. Twenty-five tumour tissues from 61 individuals with the c.2252_2253delAA mutation were tested for microsatellite instability (MSI) and protein expression. We compared the clinical features of these families versus the rest of our cohort and screened for a founder effect. All but one tumours showed the MSI-high mutator phenotype. Normal, focal and lack of MLH1 staining were observed in 16, 36 and 48 % of tumours, respectively. PMS2 expression was always lost. The mutation co-segregated with Lynch syndrome-related cancers in all informative families. All families but one fulfilled Amsterdam criteria, a frequency higher than in other MLH1 mutants. This was even more evident for AC II (72.7 vs. 57.5 %). Moreover, all families had at least one colon cancer diagnosed before 50 years and one case with multiple Lynch syndrome-related tumours. Interestingly, a statistically significant (p = 0.0057) higher frequency of pancreatic tumours was observed compared to families with other MLH1 mutations: 8.2 % of affected individuals versus 1.6 %. Haplotype analysis demonstrated a common ancestral origin of the mutation, which originated about 1,550 years ago. The mutation is currently classified as having an uncertain clinical significance. Clinical features, tissue analysis and co-segregation with disease strongly support the hypothesis that the MLH1 c.2252_2253delAA mutation has a pathogenic effect.
Introduction
Lynch syndrome (LS) is an inherited autosomal dominant cancer predisposition caused by deleterious germline Iolanda Borelli and Guido C. Casalis Cavalchini have contributed equally to this work.
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Individuals affected by LS are at high risk of developing colorectal and endometrial cancer: the most common manifestation of this syndrome are tumours in the proximal colon (from the cecum to the splenic flexure), often synchronous and/or metachronous with an early age at onset (frequently younger than 45-50 years of age). LS also confers an increased risk of developing cancer in several other organs, including ovary, stomach, small bowel, urothelium and central nervous system (CNS) [1, 2] . As a consequence of loss of MMR function, neoplastic cells from individuals with LS show an absent or altered expression of the protein corresponding to the mutated gene and a generalized genomic instability, which is particularly evident at microsatellite loci. Both features can be demonstrated on tumour specimens by immunohistochemisty and microsatellite analysis.
The MMR proteins work as heterodimers: MLH1 dimerizes with PMS2 and MSH2 with MSH6. In the absence of the usual partner, MLH1 can dimerize with PMS1 or MLH3 and MSH2 with MSH3 [3, 4] .
The majority of Lynch families have constitutional mutations in either MSH2 or MLH1 while MSH6 and PMS2 are less frequently involved. Recently, a 5-tiered classification scheme to constitutional variants in MLH1, MSH2, MSH6 and PMS2, ranging from non pathogenic/low clinical significance (Class 1) to pathogenic (Class 5), has been proposed by The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) [5] .
Germline mutations in MLH1 have been identified throughout the entire gene, and are frequently located in the ATP binding domain and in the C-terminal region which is responsible for constitutive dimerization with the PMS2 protein [6] [7] [8] [9] .
Founder mutations, i.e. inherited by numerous descendants of a common ancestor, have been reported in the MMR genes associated with LS [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .
We characterized a cohort of patients belonging to 11 LS families carrying the c.2252_2253delAA terminal mutation in the MLH1 gene. Aim of this work was to evaluate the clinical effect of this mutation and its possible founder origin given the high frequency in LS patients from Piedmont (Italy), particularly in the Turin area.
Patients and methods

Subjects and samples
The c.2252_2253delAA in MLH1 exon 19 was found in 11 apparently unrelated families among 140 families harbouring germline MMR mutations (51 in MLH1, 74 in MSH2 and 15 in MSH6) identified in index cases undergoing genetic analysis for suspected LS in the Turin Medical Genetics Unit from 2001 to middle 2013. Two hundred and seventy-eight control subjects from Piedmont were tested for the presence of the c.2252_2253delAA mutation.
Signed informed consent was obtained from all subjects included in this study, which fulfilled the policies of the local ethical committee. For each family, geographical origin was collected and pedigrees were reconstructed collecting information about the relatives' surnames going back three to five generations: no evidence that the 11 families are closely related was found.
The families carrying the c.2252_2253delAA mutation are listed in Table 1 .
Histological samples from 23 bowel and two endometrial tumours (13 from probands and 10 from family members) were retrieved for microsatellite analysis and immunohistochemistry (IHC). All tumours were revised for classification according to the WHO recommendations [22, 23] .
DNA extraction
Constitutional DNA of probands, family members and controls was obtained from peripheral blood using the QIAamp DNA Blood Mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions.
Paraffin embedded tumour sections 7-10 lm thick were manually microdissected to obtain samples with tumour cells purity over 80 %. After deparaffinization, DNAs from both tumour and normal mucosa were isolated following an overnight digestion with lysis buffer and proteinase K (Qiagen GmbH).
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissues. Slides were incubated with mouse monoclonal antibodies against the MLH1 (clone G168-15; BD PharMingen, San Diego, CA, USA), MSH2 (clone G219-1129; BD PharMingen), MSH6 (clone 44; BD Transduction Laboratories, San Jose, CA, USA), and PMS2 (clone A16-4; BD PharMingen) proteins. Visualization was performed by application of HRP-linked secondary antibody (EnVision DakoCytomation, Glostrup, Denmark) and diaminobenzidine [24] [25] [26] . IHC analysis results have been confirmed on a different sample from the same cancer.
Detection of microsatellite instability
Microsatellite instability (MSI) status was tested matching the length of three mononucleotide microsatellite markers [30] led to the identification of six Tag SNPs ( Table 2 ). The rs193922366 ins/del polymorphism in the 3 0 UTR region of MLH1 was also analyzed. Ten additional microsatellites were retrieved from UCSC (GRCh37/hg19) to complete the study. In total, 17 polymorphic markers spanning 7.8 Mb on chromosome three were tested. Markers' location on chromosome 3 and physical distance are shown in Fig. 1 .
Statistical analysis
Adjusted Chi squared statistic [31] was used to test homogeneity of proportions between groups from familyclustered data.
The age of the MLH1 c.2252_2253delAA mutation was estimated using DMLE ? 2.3, which uses Markov Chain Monte Carlo algorithm for Bayesian estimation [32] . For the population growth a rate of 1.05-fold per generation was considered according to Risch et al. [33] . Genotyped markers included seven SNPs and ten microsatellites.
Results
Eleven apparently unrelated index cases undergoing genetic analysis for suspected LS were found to carry the same mutation in the last exon of MLH1, c.2252_2253delAA (p.Lys751Serfs*3). The mutation leads to a frameshift in the mRNA and a hypothetical shorter protein due to the generation of an early stop codon after the insertion of two novel amino acids at codons 751 and 752. The c.2252_2253delAA mutation was not found in 278 controls from the Piedmont population and is not reported in the Exome Variant Server (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA, http://evs.gs.washington.edu/EVS/, accessed March 2014, release ESP6500SI-V2 including 6,503 samples). cDNA analysis, performed on 3 of 11 index cases, showed in all samples the balanced presence of both the wild-type and the r.2252_2253delAA transcript (as shown in Online Resource 1).
We subsequently extended the analysis to 61 relatives: the mutation was present in all the 12 subjects affected by LS related cancers. Among 49 healthy relatives the predictive test led to the identification of 14 additional mutation carriers, all under 50 years of age at the moment of testing (Table 1) .
Clinical features of the 11 families are summarized in Table 1 and pedigrees are available as Online Resource 2. Ten of the 11 families fulfilled the Amsterdam criteria (AC) while one family met the Bethesda criteria. Compared to the rest of the cohort (140 mutated families overall), MLH1 c.2252_2253delAA mutant families fulfilled AC more frequently than other MLH1 mutants (90.9 vs. 80 %), and this was more evident for AC II (72.7 vs. 57.5 %). All MLH1 c.2252_2253delAA mutant families had at least one colon cancer diagnosed before 50 years of age and at least one case with multiple LS related primary tumours (the latter were present in 70 of other MLH1, 77 of MSH2 and 66.6 % of MSH6 mutant families). It is noteworthy that 7/11 families (63.6 %) had more than one case with multiple LS related primary tumours, compared to 35 of other MLH1, 33.8 of MSH2 and 13.3 % of MSH6 mutant families (see Online Resource 3).
Altogether, the median age at onset of the first LS related cancer in MLH1 c.2252_2253delAA mutant families was 49 years (from 23 to 80 years): at diagnosis 30/56 subjects (53.6 %) were younger than 50, fifteen of which were below 40 years of age. Among all LS related tumours, 59/86 (68.6 %) were colorectal cancers; 37.7 % of affected individuals showed LS related extra-colonic cancers at onset from the endometrium, pancreas, stomach, small bowel, biliary tract and CNS. In particular, pancreatic cancer was more frequent (five tumours among 61 affected individuals, 8.2 %) compared to affected subjects from families with other MLH1 (1.6 %, p = 0.0057), MSH2 (2.4 %, p = 0.04) and MSH6 (3.8 %, p = n.s.) mutations. Overall, pancreatic cancer was present in 5/11 (45.4 %) of MLH1 c.2252_2253delAA families. No tumours of the upper urinary tract or the ovary nor sebaceous skin neoplasias were observed. High MSI was found in all but one analyzed tumours (96 %), in which low MSI was found, a proportion similar to MSH2 carriers in our cohort (94.6 %) but slightly higher than carriers of other MLH1 mutations (91.3 %) or MSH6 mutations (82.3 %). IHC (Fig. 2) showed complete loss of the MLH1 protein in only 12/25 (48 %) cancers; 9/25 cancers (36 %) showed a focal staining with or without weakened intensity, whereas in 4/25 specimens (16 %) MLH1 was normally expressed. For comparison purpose, analysis of 43 tumour tissues from individuals with other MLH1 mutations, all located outside exon 19, showed a normal MLH1 expression in seven (16.2 %) and a focal expression in one (2.3 %) cancers. Five of the seven cancers with normal MLH1 expression were from carriers of splicing mutations. In particular, three cancers were from carriers of the c.545?3A[G mutation, for which cDNA analysis was not performed by us but has been shown to cause aberrant splicing leading to the creation of a premature stop codon [34] and two from carriers of the c.589-2A[G mutation, for which cDNA analysis showed the skipping of the first four bases of exon eight leading to a frameshift and the creation of a premature stop codon. The remaining mutations in which a normal MLH1 expression was observed were an in frame deletion in exon 16 and a truncating mutation in exon 18. The colon cancer with focal MLH1 expression was from a female carrier of the splicing defect c.589-17T[A in which RNA-cDNA analysis showed the in frame retention of the last 15 nucleotides of intron 7.
Normal MLH1 expression was found in normal mucosa adjacent to cancer in all samples. In the 23 tumours from individuals with the c.2252_2253delAA mutation tested for Table 2 ) and includes the CTT deletion polymorphism in the 3 0 UTR of MLH1 (c.*35_*37delCTT, rs193922366). In family M1/19-8, for which only the index case was available, the markers' phase was deducted on the basis of the CEU haplotypes: only two SNPs' phases were possible, one of which coincided with the ''mutated'' haplotype. This was not possible for the index case of family M1/19-7 in which different phases were possible, while M1/19-9 was homozygote for the SNPs defining CEU ''haplotype two''.
It is noteworthy that the genotypes of the 4 families that aren't fully informative are compatible with the same 1.7 Mb haplotype mentioned above (Table 4) .
The age of the c.2252_2253delAA mutation predicted by the DMLE?2.3 software is 62 generations (95 % CI 28-96), corresponding to about 1,550 years.
The wild-type haplotypes identified in our families are listed in Online Resource 4 and match six out of eight CEU haplotypes as defined by tag SNPs. Taking into consideration microsatellites, 23 different haplotypes were defined. The shared region in wild-type haplotypes spans about 0.1 Mb, compared to 1.7 Mb in the ''mutated'' haplotype. Only two haplotypes (2.pol), both belonging to CEU ''haplotype 2'', carry the rs193922366 delCTT polymorphism and overlap with the ''mutation-haplotype'' for the same 0.1 Mb region mentioned above, but differ for the majority of microsatellites.
Discussion
The MLH1 c.2252_2253delAA mutation is the most frequently recurring LS mutation found in our laboratory: apart from a MSH2 exon eight deletion with founder effect identified in eight Sardinian families [21] , the other recurrent mutations were found in 2-4 different families only. Overall, 21.6 % of the families with a MLH1 mutation identified in our laboratory carried the c.2252_2253delAA mutation. The six other recurrent MLH1 mutations found in our cohort have not been tested for a founder effect.
The c.2252_2253delAA mutation has previously been reported in the InSiGHT LOVD database (http://www. insight-group.org/variants/database/) in a Korean family [35] [36] [37] , a Danish family [38] , and in three other occurrences as unpublished data from the UK, Germany and Australia. No details about families nor tumour tissue analysis are available.
Two different mutations involving the same nucleotides are also reported in the LOVD database. The missense variant c.2252A[G (p.Lys751Arg) has been classified as likely not pathogenic (Class 2). The duplication c.2252_2253dupAA, which leads to a frameshift in the mRNA and is predicted to result in a protein longer by 26 amino acids, has been reported in three different families either with MSI-H and lack of MLH1 expression [39] , MSS (no information on MLH1 expression) [40] or in which tumour tissue had not been tested [41] and has been classified as uncertain (Class 3). The finding of both deletions and duplications of the same nucleotides in different cohorts may be explained by presence of three consecutive Adenines in the position c.2251_2253.
Many founder mutations associated with LS have been reported in the MLH1 gene [10] [11] [12] [13] [14] [15] . In Italy, a founder MLH1 mutation was found in six Lynch families originating from a relatively small geographic area of Northern Italy [42, 43] and three other have been described in Southern Italy [44] .
Haplotype analysis of the 11 families with the c.2252_2253delAA mutation showed a shared haplotype spanning 1.7 Mb in all eight fully informative families. It is of note that the heterozygous markers in the three remaining families are compatible with this ''mutation-haplotype''. The shared haplotype includes the CTT deletion in the 3'UTR region, which is present in only two wild-type haplotypes (see Online Resource 4). As these matched the ''mutation-haplotype'' for some 0.1 Mb, we can assume that the c.*35_*37delCTT deletion was the first mutational event on the ancestral ''CEU 2'' haplotype, followed by further recombination or microsatellite mutations, and lastly by the occurrence of the c.2252_2253delAA mutation, about 1,550 years ago.
The evidence of a common ancestor obtained by haplotype analysis is coherent with the geographical origin of the 11 families, all from a 45 km-wide area south of Turin, Piedmont.
Clinical data showed a high cancer incidence in families carrying the c.2252_2253delAA mutation. A higher proportion of families fulfilled AC compared to other MLH1 mutants, and this was more evident for AC II. All families had at least one colon cancer diagnosed before 50 years of age and at least one case with multiple LS related primary tumours; almost two-thirds of the families had more than one case with multiple LS related primary tumours.
A high frequency of extra-colonic cancer was observed in subjects with the c.2252_2253delAA mutation. Interestingly, pancreatic cancer was significantly more frequent compared to carriers of other MLH1 mutations. Overall, 45.4 % of families reported the presence of pancreatic cancer. This is higher than the frequencies reported up to date in other surveys, none of which was over 25 % [45] [46] [47] . Our data are evocative of an increased pancreatic cancer risk in families with the c.2252_2253delAA mutation. Since haplotype analysis demonstrated a common origin of the 11 families, we cannot rule out that the observed increased frequence of pancreatic cancer is actually due to another shared factor of genetic predisposition. However, to our knowledge no genes with a demonstrated role in pancreatic cancer are located inside the haplotype shared by the families carrying the mutation.
No tumours of the upper urinary tract and the ovary were observed. This is consistent with published data, as they are more frequently observed in MSH2 [48] and MSH6 [49] mutated families, respectively.
Tissue analysis showed high MSI in all but one tested tumours from subjects with the c.2252_2253delAA mutation.
In contrast, complete loss of MLH1 expression was found in only about half of the analyzed tumours, whereas about one-third had focal immunostaining and the remaining had normal expression. Unusual staining patterns have been previously reported and do not seem to depend on the anti-MLH1 antibody used [50] . It has been suggested that different kinds of second hits can result in variable MLH1 immunostaining patterns in tumours of individuals carrying the same germinal mutation [51] . The possible association of the c.2252_2253delAA mutation with different somatic mutations in the wild type allele may lead to different expression patterns, from the complete absence of the MLH1 protein to the complete expression of a non-functional protein product. IHC analysis results support this hypothesis, considering that in all three cases in which distinct tumours from the same patient were analyzed, clearly different immunostaining patterns were observed (Table 3) .
A positive IHC staining may be explained by the presence of a mutant MLH1 protein catalytically inactive but antigenically intact. This has been shown for some missense mutations in the N-terminal ATPase pocket or in the C-terminal PMS2 binding region, which show an impaired MMR activity and no decrease in protein expression [52] [53] [54] . Normal MLH1 expression, however, has also been described in tumours from subjects with small and large inframe deletions and truncating mutations [51, 55] . As the c.2252_2253delAA mutation is located in the last exon of MLH1, it is unlikely that the mutant mRNA is degraded by nonsense-mediated decay (NMD) [56] . Accordingly, Sanger sequencing of cDNA by three different carriers showed the balanced presence of both the wild-type and mutated transcripts (as shown in Online Resource 1). It is of note that Sanger sequencing is not a quantitative method and may therefore miss small imbalances that might be detected using more sensitive techniques (i.e. primer extension). The presence of the mutated transcript, however, does not necessarily imply that the mutant MLH1 protein is correctly expressed nor stable.
It has been previously reported that terminal MLH1 defects prevent the formation of a stable complex with PMS2, resulting in an impaired DNA mismatch repair function [6, 9] . Although dimerization is not required for nuclear localization, the MLH1-PMS2 heterodimer is imported in the nucleus more efficiently than either MLH1 or PMS2 monomers [57] . While the MLH1 protein is stable when expressed alone, PMS2 is quickly degraded if not bound to MLH1 [9] .
The c.2252_2253delAA mutation is predicted to abolish 6 of the last 8 MLH1 amino acids, which are highly conserved in the evolution of eukaryotes (as shown in Online Resource 5) and therefore, even if the mutant MLH1 protein is expressed, it is likely that binding to PMS2 is impaired. Accordingly, PMS2 expression was lost in all analyzed tumour samples from individuals carrying the c.2252_2253delAA mutation.
In our cohort, a normal MLH1 expression was not limited to tumours from individuals with the c.2252_2253delAA mutation as it was observed with the same frequency in tumours from individuals with other MLH1 mutations, all of which located outside exon 19 and all but one resulting in a stop codon. Unfortunately, data about IHC testing for PMS2 is not available for these cases as it was not routinely performed years ago.
Although the mechanism leading to MLH1 protein focal expression has not been clarified, it is noteworthy that in our experience this abnormal pattern has not been identified in patients with other MLH1 mutations, with the exception of one tumour from a subject with a different MLH1 mutation, a splicing defect leading to the in frame retention of the last 15 nucleotides of intron 7.
The antigenic epitopes for the four anti-MMR antibodies are particularly sensitive to fixation and therefore immunostaining patterns should only be assessed in well-fixed regions of the tissue section [26] . In our experience of IHC analysis, only few tumour tissues have shown weak, focal or weak focal MMR protein staining. These expression patterns, however, were usually seen for more than one protein in the same specimen and were interpreted as inadequacy of the sample. In the present study we did exclude that focal staining was due to tissue poor preservation, since normal MLH1 expression was found in the normal mucosa adjacent to cancer in all samples, or to an erroneous interpretation due to the mucinous component of the tumour; moreover MSH2 and MSH6 proteins were normally expressed in the nuclei of both cancer and normal mucosa of all samples. The focal MLH1 expression was unrelated to histological features of the analyzed tumours (cancer site, grading, mucinous component). We can speculate that this very terminal frameshift mutation leads to a MLH1 protein not only unable to hetero-dimerize with PMS2 but also less stable and/or with a less efficient nuclear import as a monomer, which would explain its proper expression in only a few nuclei.
The c.2252_2253delAA mutation has been classified as Class 3 (uncertain) by the Variant Interpretation Committee of the InSiGHT, mainly due to insufficient evidence. No familial or clinical data about previously reported cases is available.
Our data strongly support the hypothesis that the MLH1 c.2252_2253delAA mutation has a pathogenic effect. The mutation is predicted to abolish six of the highly conserved last eight amino acids of MLH1, in the C-terminal region which is responsible for constitutive dimerization with the PMS2 protein. Accordingly, all tested tumours from individual with the mutation lack PMS2 expression and all but one show MSI-H.
The mutation co-segregates with disease in all informative families: it is noteworthy that all healthy subjects who were over 50 years of age at the moment of testing, including four aged 61-77, do not carry the mutation. The mutated families showed clinical features typical of LS including tumours at young age and multiple primary tumours in the same subject. Moreover, a high frequency of pancreatic cancer was observed.
The c.2252_2253delAA mutation was absent in control subjects from the same Italian region and has not been reported as a normal polymorphism in the general population.
Since haplotype analysis demonstrated a single origin of the mutated allele, we cannot rule out that the cause of LS in the 11 tested families is actually an unidentified MLH1 mutation residing on the same haplotype. This however is unlikely considering that the c.2252_2253delAA mutation has been reported in other two families ascertained for LS in different populations.
